1-11 of 11
Hideki Ishihara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-09-05: Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation

Arisa Nishimukai, Naoya Shibata, Wataru Kikuchi, Hiroki Hutawatari, Hideki Ishihara, Yasuo Miyoshi
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-09-05.
https://doi.org/10.1158/1538-7445.SABCS14-P5-09-05
Published: 01 May 2015
View articletitled, Abstract P5-09-05: Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation
Journal Articles

Abstract 299: CDK1 and CDK2 activity is a strong predictor of renal cell cancer recurrence

Fumiya Hongo, Natsuki Takaha, Yasunori Kimura, Terukazu Nakamura, Kazuya Mikami, Satoshi Nakayama, Tomoko Matsushima, Hideki Ishihara, Toshiyuki Sakai, Tsuneharu Miki
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 299.
https://doi.org/10.1158/1538-7445.AM2011-299
Published: 15 April 2011
View articletitled, Abstract 299: CDK1 and CDK2 activity is a strong predictor of renal cell cancer recurrence
Journal Articles

Abstract 3730: Akt activity is suppressed by doxorubicin through downregulation of ErbB receptors and its enhanced activity is associated with higher sensitivity to doxorubicin in breast cancer

Amane Harada, Chihiro Suminaka, Tomoko Oyama, Keigo Gohda, Hideki Ishihara, Seung Jin Kim, Shinzaburo Noguchi
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3730.
https://doi.org/10.1158/1538-7445.AM10-3730
Published: 15 April 2010
View articletitled, Abstract 3730: Akt activity is suppressed by doxorubicin through downregulation of ErbB receptors and its enhanced activity is associated with higher sensitivity to doxorubicin in breast cancer
Journal Articles

Abstract #5556: Understanding biological rationale for specific activity of CDK1 and CDK2 as a prognostic marker of breast cancer recurrence

masaki shibayama, Shigehiro Numada, Tomoko Matsushima, Satoshi Nakayama, Tadashi Kiniwa, Amane Harada, Seung Kim, Atsushi Shimomura, Shinzaburo Noguchi, Hideki Ishihara
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5556.
Published: 01 May 2009
View articletitled, Abstract #5556: Understanding biological rationale for specific activity of CDK1 and CDK2 as a prognostic marker of breast cancer recurrence
Journal Articles

Newly established one-step methylation specific PCR (OS-MSP) for breast cancer screening and monitoring system

Masahiro Kajita, Noriaki Yamamoto, Yasuo Miyoshi, Ayako Sakai, Xuan Dai, Hideki Ishihara, Shinzaburo Noguchi
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3660.
Published: 01 May 2008
View articletitled, Newly established one-step methylation specific PCR (OS-MSP) for breast cancer screening and monitoring system
Journal Articles

A biological significance of ratio of CDK2 to CDK1 specific activity

Tomoko Matsushima, Tadashi Kiniwa, Yasuhiro Torikoshi, Satoshi Nakayama, Shigeyuki Tamura, Masaki Shibayama, Yuko Kawasaki, Aya Katayama, Yuko Koyama, Yasuo Miyoshi, Seung Jin Kim, Shinzaburo Noguchi, Hideki Ishihara
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3494.
Published: 01 May 2007
View articletitled, A biological significance of ratio of CDK2 to CDK1 specific activity
Journal Articles

Cyclin-dependent kinase (CDK) profiling to predict paclitaxel chemosensitivity.

Naoto T. Ueno, Torikoshi Yasuhiro, Satoshi Nakayama, Takeshi Takahashi, Tamotsu Sudo, Tomoko Matsushima, Tomokazu Yoshida, W. Fraser Symmans, Lajos Pusztai, Gabriel N. Hortobagyi, Hideki Ishihara
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 107.
Published: 01 May 2005
View articletitled, Cyclin-dependent kinase (CDK) profiling to predict paclitaxel chemosensitivity.
Journal Articles

Novel mechanism reduces proliferation of clear cell carcinoma of the ovary: cyclin-dependent kinase 2 (CDK2) activity is reduced by cytoplasmic sequestration of CDK2 by phosphorylated p27

Hiroaki Itamochi, Tomokazu Yoshida, Daisuke Aoki, Hideki Ishihara, Junzo Kigawa, Nao Suzuki, Shiro Nozawa, Naoki Terakawa, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1283.
Published: 01 May 2005
View articletitled, Novel mechanism reduces proliferation of clear cell carcinoma of the ovary: cyclin-dependent kinase 2 (CDK2) activity is reduced by cytoplasmic sequestration of CDK2 by phosphorylated p27
Journal Articles

CDK profiling of gastrointestinal carcinoma tissues.

Hideki Ishihara, Tomokazu Yoshida, Yuko Kawasaki, Hironori Kobayashi, Masatoshi Yamasaki, Satoshi Nakayama, Erika Miki, Kei-Ichiro Shohmi, Tomoko Matsushima, Sachiyo Tada, Masakatsu Morita, Yoko Hino, Jun Kamiyama, Yoshihiro Sowa, Yasunari Tsuchihashi, Hisakazu Yamagishi, Toshiyuki Sakai
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 844–845.
Published: 01 April 2004
View articletitled, CDK profiling of gastrointestinal carcinoma tissues.
Journal Articles

Preferential Expression of Immunoreactive Fucosylceramide in Adenocarcinoma of the Lung

Hiroyuki Yamada, Hideki Ishihara, Hiroshi Kitagawa, Yoshinori Kawabata, Shinji Itoyama, Isamu Sugawara
Journal: Cancer Research
Cancer Res (1992) 52 (16): 4408–4412.
Published: 01 August 1992
View articletitled, Preferential Expression of Immunoreactive Fucosylceramide in Adenocarcinoma of the Lung
Open the PDF for Preferential Expression of Immunoreactive Fucosylceramide in Adenocarcinoma of the Lung in another window
Journal Articles

Establishment and Characterization of a Mouse Monoclonal Anti-Fucosylceramide Antibody, PC47H

Hideki Ishihara, Hiroshi Hattori
Journal: Cancer Research
Cancer Res (1991) 51 (16): 4182–4186.
Published: 01 August 1991
View articletitled, Establishment and Characterization of a Mouse Monoclonal Anti-Fucosylceramide Antibody, PC47H
Open the PDF for Establishment and Characterization of a Mouse Monoclonal Anti-Fucosylceramide Antibody, PC47H in another window